Drug intelligence / Profile preview

PNQ-401

Development stage: Preclinical
Lead developer: Vyome Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

PNQ-401 is an oral small molecule Janus kinase (JAK) inhibitor developed by Impetis Biosciences, with an exclusive license granted to Vyome Holdings. It is specifically designed to selectively inhibit JAK1 and JAK3 while sparing JAK2, a strategy aimed at reducing hematological toxicities often associated with non-selective JAK inhibition. The drug is currently in the IND-ready stage for the treatment of autoimmune diseases, including psoriasis and rheumatoid arthritis.

Targets

JAK3 (Janus kinase 3)

Beyond the preview

Go deeper on PNQ-401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PNQ-401.

Explore the full profile